VSGC12

VSGC12 is a highly potent non-clinical glucocorticoid compound developed for asthma treatment. It acts as an agonist of the glucocorticoid receptor, delivering enhanced anti-inflammatory activity both in cell-based and animal models compared to fluticasone furoate, a leading clinical inhaled glucocorticoid. VSGC12 significantly suppresses asthma-related inflammation, cytokines, and airway hyper-responsiveness in mouse models, and demonstrates a superior safety profile (lower insulin resistance and bone loss) at effective doses. VSGC12’s design is based on structural modifications to optimize glucocorticoid receptor potency, mainly for inhaled use, though in-vivo studies used intraperitoneal administration. It is not yet a marketed pharmaceutical and remains a research-stage candidate[1][2][3][4].